Clinical trial · no report yet · Phase 2
TRUST-II
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
- NCT04919811 ↗
- Active not recruiting
- Nuvation Bio Inc.
- 19 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 10 | |
| YouTube | 7 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Taletrectinib
- Arms
- Taletrectinib · Experimental
- Enrollment
- 217
- Primary outcomes
- Objective response rate (ORR) by independent radiology review committee (IRC)
- Sponsor
- Nuvation Bio Inc.
- Start
- Sep 1, 2021
- Primary completion
- Jun 11, 2025
- Results posted
- No
- Registry record
- NCT04919811 · updated Jan 7, 2026
Publications
linked from the registry- Perol M, Li W, Pennell NA, Liu G, Ohe Y, De Braud F, Nagasaka M, Felip E, Xiong A, Zhang Y, Fan H, Wang X, Li S, Lai RK, Ran F, Zhang X, Chen W, Bazhenova L, Zhou C. Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST. J Clin Oncol. 2025 Jun;43(16):1920-1929. doi: 10.1200/JCO-25-00275. Epub 2025 Apr 3. PubMed 40179330
- Nagasaka M, Ohe Y, Zhou C, Choi CM, Yang N, Liu G, Felip E, Perol M, Besse B, Nieva J, Raez L, Pennell NA, Dimou A, Marinis F, Ciardiello F, Seto T, Hu Z, Pan M, Wang W, Li S, Ou SI. TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors. Future Oncol. 2023 Jan;19(2):123-135. doi: 10.2217/fon-2022-1059. Epub 2023 Mar 6. PubMed 36877099